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Vascular Studies Unit, Bristol Royal Infirmary, Bristol, U.K. 
Objectives: The incidence of vein graft stenosis ranges from 5%-45%. Reported rates appear to be increasing as 
technological dvances make detection easier. The aim of this study was to review our experiences with regard to the 
incidence of stenosis in infrainguinal bypass grafts and the outcome of intervention for salvage of failing grafts. 
Design: Retrospective review of graft surveillance r cords. 
Setting: Vascular Studies Unit, Bristol Royal Infirmary. 
Methods: A Duplex-based graft surveillance (GS) programme was used from January 1989 to June 1994 to study 275 
primary graft procedures in250 patients with Io~Oer limb ischaemia. Patients were scanned at 1 week, 6 weeks and 3, 6, 
9 and 12 months postoperatively. 
Results: One year cumulative limb salvage, patient survival and primary, primary assisted and secondary patencies were 
91%, 83%, 67%, 77% and 84% respectively. Duplex scanning detected 85 vein graft stenoses in59 patients: an incidence 
of 21.5%. In addition, 64 potentially graft-threatening flow (14) and outflow (50) problems were detected in the native 
vessels of 52 patients from clamp damage or progression ofdisease (POD). 
Of the 85 graft stenoses, 40 were treated by balloon angioplasty (PTA) and 20 by surgical intervention and 1 patient's 
symptoms were treated by chemical sympathectomy. Twenty-four patients were not actively treated. Of the 64 grafts 
affected by POD, 20 were treated by PTA, 15 by surgery, one with anti-coagulation a d 28 had no treatment. Comparing 
patients with non-treated and treated lesions, the respective 12 month cumulative patencies for patients with graft stenoses 
were 75% and 87.5% as against 86% and 83% for patients with POD (log rank test : p > 0.1). 
Conclusions: These results uphold the perceived benefits of a GS programme, although the evidence from the non-treated 
cases in this series reinforces a need for a large, prospective, randomised trial to confirm the case for GS. 
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Introduction 
Ever since Szilagyi studied the biological fate of 
femoropopliteal bypass grafts and reported the devel- 
opment of fibrous strictures due to intimal hyperplasia 
in nearly 30% of vein grafts, 1 postoperative graft 
surveillance (GS) programmes have been advocated 
for the detection of stenotic lesions which when 
treated appropriately may salvage the "at risk" graft 
f 23 rom occlusion.' GS is justified if progression from 
stenosis to ~occlusion is inevitable and if intervention 
prolongs graft survival. Other 'causes of graft failure 
include technical errors and dysplastic, narrowed 
segments in non-compliant, hickened, post-phlebitic 
Veins of substandard quality. 
The proponents of GS draw evidence from the 
growing literature reporting impressive secondary 
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patencies following intervention. 2'4--9 Moody et al. 
reported significantly enhanced cumulative patencies 
when comparing a group of screened grafts with 
historical controls for whom GS was unavailable 2 but, 
to date, there has been only one small, prospective, 
randomised trial on GS comparing two different 
surveillance programmes (with and without duplex 
scanning). 1° The Swedish group studied patients for 3 
years following surgery and reported the comparative 
patency rates following intervention, finding in favour 
of the Duplex GS regimen. 1° 
The true incidence of vein graft stenosis remains 
uncertain ranging from 5% 11 to 45%. 12 It is generally 
accepted that follow-up should be most intense 
during the first year and that sensitive, reproducible, 
non-invasive methods are superior to clinical scrutiny 
on the one hand and preferable to arteriography on 
the other hand. 3 However, there are no standardised 
regimens for GS and there have been no large, 
prospective, randomised trials to compare the results 
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of GS with no surveillance. In consequence, the criteria 
used to diagnose "at risk" grafts, the optimal tech- 
nique for surveillance and the best method of inter- 
vention are widely debated. 13 There is also con- 
troversy as to the natural history of untreated vein 
graft stenoses. 
This retrospective study was undertaken to review 
our 5 year experience with the GS programme at 
Bristol Royal Infirmary, with particular interest in the 
incidence of stenosis in this series and the outcome of 
intervention for salvage of failing grafts. 
Material and Methods 
A GS programme has been operational in this Unit 
since 1989. Between then and June 1994, 275 primary 
grafts in 250 consecutive patients (80% male, 37% 
diabetic) were recruited onto the programme. Sixty- 
two per cent of grafts were for limb threatening critical 
ischaemia, 35% for severe, limiting claudication (exer- 
cise tolerance less than 100 yards) and 3% were for 
asymptomatic, but enlarging popliteal aneurysms. 
Ninety-seven grafts were anastomosed onto the 
above-knee popliteal artery, the remainder were infra- 
geniculate (71 distal/pedal grafts). Vein was the 
conduit of choice for 251 grafts (149 in situ, 60 
reversed, 27 non-reversed, 4 arm vein and 11 compos- 
ite) and polytetrafluoroethylene was used in the 
remaining cases. Postoperativel)~ patients were main- 
tained on daily low-dose Aspirin. 
Scanning was initially carried out using a black and 
white Technicare Autosector Duplex scanner (Techni- 
care Corporation, Cleveland, Ohio, U.S.A.). In 1990, 
this was replaced by an ATL Ultramark 9 colour 
Duplex scanner (Advanced Technology Laboratories, 
Stevenage, U.K.) and in October 1992, the HDI 
upgraded version was installed. An "at-risk" graft 
was defined as one with slow flow, designated by 
peak mean velocities (PMV) less than 45 cm/s, a fall of 
at least 0.1 in the ankle-brachial Doppler pressure 
index (ABPI) and/or a focal velocity disturbance, 
designated by a V2/V1 ratio greater than 2.0 (where V 2 
is the peak systolic velocity at a stenosis and V1 is the 
peak systolic velocity at any other non-stenosed point 
within 2cm). 
Duplex scans were performed at 1 week, 6 weeks 
and 3, 6, 9 and 12 months postoperatively, using a 
5MHz linear array transducer to record PMV's along 
the graft. At each visit, symptoms, smoking habit and 
medication and resting Doppler ABPI's were 
recorded. Additional visits for more intensive surveil- 
lance were arranged at the discretion of the scanning 
technologist according to findings and a policy of 
open self-referral was adopted for patients developing 
symptoms between scheduled visits in order to avoid 
delay in the face of a critical stenosis or recent 
thrombosis. 
Patients with Duplex-detected stenoses underwent 
arteriography and treatment of suitable lesions by 
percutaneous balloon angioplasty (PTA) at the discre- 
tion of the radiologist. PTA was the treatment of 
choice for short, discrete lesions, particularly in the 
body of the graft. In the event of a lesion being 
unsuitable for PTA, a patch angioplasty, an inter- 
position graft or a jump graft were performed as 
appropriate. 
The GS records and medical case-notes of all 
patients involved in GS during the study period were 
reviewed to investigate the incidence of vein graft 
stenosis and to evaluate the influence of intervention. 
Cumulative patency and life-table data were analysed 
according to the methods recommended by the Ad 
Hoc Committee on Reporting Standards. 14 
Results 
The mean follow-up for this series was 10.5 months 
(range 2 weeks--48 months). Eighty-five vein graft 
stenoses were detected in 59 patients by Duplex 
scanning (~ 50% stenosis) and subsequently con- 
firmed by arteriography, an incidence of 21.5%. 
Stenoses were detected at a mean follow-up of 6.9 
months (range 1 week-30 months). Thirteen stenoses 
(15.2%) developed at the 12 month stage or later. 
Treatment for graft stenoses i  shown in Table 1. 
Radiologically-successful PTA resulted in a median 
rise in the ABPI of 0.25 (range 0.06-0.46). Successful 
surgical intervention resulted in a median rise in the 
ABPI of 0.34 (range 0.00-0.76). Of 40 stenoses treated 
by PTA, 12 recurred and warranted further inter- 
vention : four were treated by surgery and eight by 
repeat PTA, supplemented by stent insertion in four 
cases. These re-do PTA's were successful for the 
remainder of the GS (median follow-up interval 10 
Table 1. Modes of intervention for salvage of threatened grafts 
Number No 
of lesions PTA Surgical Sy A/C treatment 
Stenosis 85 40 20 1 0 24 
POD 64 20 15 0 1 28 
PTA=percutaneous transluminal ngioplasty; Sy=sympathectomy; 
A/C=anti-eoagulants; POD=progression of atherosclerosis in native 
vessels. 
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months; range 2-21 months) and there were no 
complications attributable to PTA alone. 
In addition, 64 potentially graft-threatening prob- 
lems in 52 patients were detected in the native vessels 
either proximal or distal to the graft due to progressive 
atherosclerotic disease (POD). For the majority of 
these grafts, POD was attributable tothe outflow tract, 
but in 14, there were inflow problems. Treatment for 
POD is also shown in Table 1. Thirteen (20%) of the 64 
lesions due to POD occurred at 12 months or later. 
The 12 month limb salvage, patient survival and 
primary, primary assisted and secondary cumulative 
patencies were 91%, 83%, 67%, 77% and 84% respec- 
tively. The life table analyses are shown in Fig. 1. There 
was a significant difference between the primary and 
primary assisted and the primary and secondary 
patencies at 12 months (p < 0.001 using the log rank 
test). The respective 3 year limb salvage, patient 
survival and primary, primary assisted and secondary 
cumulative patencies were 86%, 68%, 49%, 59% and 
69%. 
Despite meeting the criteria for "at risk" grafts 
outlined above, 24 of the 85 graft stenoses and 28 of 
the 64 lesions due to POD were not treated for various 
reasons, including unacceptably high risk of inter- 
vention over conservative management, loss of all 
named run-off vessels, compromised patient fitness 
and refusal by the patient to consent o proposed 
treatment. Whilst accepting that these non-rando- 
mised groups may not be directly comparable, never- 
theless, both non-treated and treated grafts fulfilled 
the designated Duplex criteria. The respective 12 
month primary cumulative patencies for non-treated 
and treated patients with graft stenoses were 75% and 
87.5% respectively (Fig. 2a) and for patients with 
grafts threatened by POD, they were 86% and 83% 
respectively (Fig. 2b). (For both Figs. 2a and b, the 
numbers represent patients with potentially "at risk" 
grafts at the beginning of each time interval rather 
than numbers of lesions. Numbers at 36 months were 
too small to be meaningful). For both stenoses and 
POD, there were no significant differences in the 12 
month cumulative patencies for patients treated con- 
servatively or actively (p > 0.1 using the log rank 
test). 
Discussion 
These results are in keeping with other published 
series 2'4'7-9 and uphold the benefits of GS pro- 
grammes, with significantly enhanced primary 
assisted and secondary cumulative patency rates 
when compared with primary patencies in the same 
series. The incidence of vein graft stenosis of 20% is 
also in keeping with many other published 
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Fig. 1. Life-tables howing primar~ primary-assisted and secondary patencies for the series. (p < 0.001 refers to the significant difference 
between primary and primary-assisted cumulative patencies and between primary and secondary cumulative patencies using the log rank 
test. Numbers above chart represent numbers of grafts at risk at the beginning of each interval and refer to secondar35 primary-assisted and 
primary patencies respectively, reading from top to bottom). ( - - )  primary patency; (- - -) primary assisted patency; (....) secondary 
patency. 
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cult due to the marked lack of standards in reporting 
on all aspects of GS. 
When reviewing the literature, the variation in the 
recommended regimens, criteria and modes of inter- 
vention are striking. The ideal GS method should be 
non-invasive, simple, reproducible, cost-effective and 
highly sensitive and specific. Some series have relied 
solely on clinical examination and serial measure- 
ments of ABPI's, 6 others use ABPI's and Duplex 
scanning, 7'16A7 ABPI's, Duplex and digital subtraction 
arteriography 2'1s and Duplex alone, s'~9 Unfortunatel~ 
simple ABPI's have been shown to be-unreliable, since 
the presence of graft-threatening stenoses is underesti- 
mated. In Cohen's series, which relied on ABPI's 
alone, there was a stenosis incidence of only 9%. 6 
Wolfe et al. found that ABPI's failed to detect up to 
50% of arteriographically proven stenoses 2° and 
Barnes et al. found that patients developing a drop in 
resting ABPI of more than 0.2 were at no greater isk of 
graft failure than patients with stable ABPI's following 
surgeryY Taylor et al. claimed almost perfect sensitiv- 
ities and specificities for Duplex when using the 
simultaneous criteria of Vu/V1 > 2.0 and PMV < 45 
cm/s ,  as used in this study, 19 whilst Sladen et al. also 
recommended combined use of Duplex-derived low 
and high velocity criteria, but used a V2/V1 ratio of 3.0 
or more to distinguish stenoses of between 60% and 
80%.22 In an earlier report from our group, Davies et al. 
compared ABPI's, Duplex scanning and impedance 
analysis and concluded that colour Duplex was the 
most sensitive, non-invasive modal i ty for detection of 
stenoses as long as velocity ratios and absolute 
velocity measurements were considered together. 13 
The frequency of surveillance visits is also highly 
variable, the initial scan ranging from 1 week, 3'1° to 1 
month, 9'13 6 weeks 19 and 3 months 2° following sur- 
gery and the programme continuing for up to 9 
months, 3 12 months 2'11'19 and 3 years. 1° As the 
majority of intimal hyperplastic lesions appear 
between 1 and 12 months postoperatively, most 
regimes intensify GS during this interval  but even 
here, there are variations in accepted practice with 
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Fig. 2. (a) Life-tables howing 12 month cumulative patencies for patients with non-treated and non-treated graft stenoses. Numbers 
represent grafts at risk at beginning of each interval and refer to treated and non-treated grafts respectively, reading from top to bottom. 
(--) treated stenosed grafts; (- - -) non-treated stenosed grafts. (b) Life-tables showing 12 month cumulative patencies for patients with non- 
treated and treated grafts threatened by progression of disease in either inflow or outflow vessels. (Numbers represent grafts at risk at 
beginning of each interval and refer to non-treated and treated grafts respectively, reading from top to bottom). (--) treated grafts + POD; 
(- - -) non-treated grafts + POD. 
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some programmes reviewing patients 3 monthly 2'~1 
and some 6 monthlyF The graft stenoses and the cases 
of POD in native vessels which developed after 12 
months and accounted for 17% of the total number of 
detectable sions in this series raise the question as to 
whether GS should be extended beyond 12 months. A 
prospective, randomised trial might help to clarify this 
issue. 
The recurrence of symptoms and the progression 
from stenosis to occlusion 15 are the rationale for GS 
and the justification for intervention. This view is 
supported by the poor results of revising a throm- 
bosed graft compared to salvaging a functioning, 
albeit threatened bypass. 4'6'7'23'24 However, the lack of 
a significant difference between the treated and non- 
treated grafts in both the stenosis and POD groups in 
this series calls into question the inevitability of 
stenosis progression and raises the issue of possible 
unnecessary treatment, although it is accepted that 
overall numbers are small and these findings may 
represent a Type II statistical error. There is little data 
available on the natural history of untreated, asympto- 
matic but, haemodynamically significant lesions. 17 
The occasional ong-term success of conservative 
treatment in patients with poor haemodynamic indi- 
ces 25 suggests that some stenoses may adopt a benign 
course and may not warrant intervention. By contrast, 
the occurrence of graft occlusion without warning 
despite regular surveillance suggests that some steno- 
tic lesions are more aggressive or that some grafts fail 
for reasons other than stenosis or POD, such as poor 
cardiac output with reduced peripheral perfusion. 
Green et aI. recommended active treatment of asymp- 
tomatic stenoses only if the combination of ABPI's and 
Duplex scans were abnormal; otherwise they sug- 
gested a conservative policy with intensified GS until 
symptoms developed and/or both parameters became 
abnormal. ~7 As in this series, Idu et al. had several non- 
treated patients with stenoses and found that non- 
treatment was only safe for lesions causing up to 50% 
diameter reduction which gives added credence to use 
of the V2/V ~ ratio during Duplex scanning. 8 Mattos et 
al. also had a number of non-treated patients with 
stenosed grafts in their series and concluded that 
whilst intervention prolonged patencN most stenosed 
grafts remained patent if left alone and therefore 
stenosis was just one factor relevant to the overall 
aetiology of failure. 26 
There are no universally-accepted guidelines as to 
the most effective modality for intervention. Most 
series report a mix of radiological and surgical 
interventions and it is generally accepted that PTA is 
most suited to short lesions less than 2cm. 3 In our 
experience, PTA provides a safe, durable and effective 
treatment option for stenoses and does not preclude a
repeat attempt or a surgical option in the event of 
recurrence. 
In conclusion, our data support he principles of GS, 
based on the assumption that every haemodynam- 
ically-significant lesion detected poses a threat to 
continuing graft integrity and that intervention is 
warranted to salvage the threatened graft before it 
occludes. However, this review has identified a sub- 
set of patients with "at-risk grafts" who did not have 
the stenoses corrected. Although no clear distinguish- 
ing factors have been identified to discriminate these 
stenoses from the ones which were treated, and 
accepting that there may be some bias due to patient 
selection, the results for the non-treated lesions sug- 
gest that intervention is not warranted in every case 
and they uphold the need for a large, prospective, 
randomised trial to formally establish the role of GS. 
The need for standardisation f protocols, criteria and 
modes of intervention remains outstanding. 
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